CXCL8 and ovarian carcinoma: OPN, MIF, anti-IL-8 AAb and CA125 levels were measured in an independent validation set of sera from 71 patients with early stage ovarian cancer, 45 patients with late stage ovarian cancer and 131 healthy participants in the NROSS trial.